MOUNT SINAI
RESIDENCY PROGRAM
IN PSYCHIATRY

Department of Psychiatry
Icahn School of Medicine at Mount Sinai
Welcome to Mount Sinai. We are very pleased that you are interested in embarking on your career in psychiatry at Icahn School of Medicine at Mount Sinai.

We consider psychiatry to be the most interesting and challenging specialty in medicine, charged with caring for those who otherwise would lead troubled lives, with risk of exclusion, isolation, and suicide. These illnesses result from complex pathways involving genetic predispositions, the development of mind, cognitive-behavioral traits, personal meanings, and interactions with adverse or beneficial social and material environments. We now have potent treatments that are constantly being refined. Our psychotherapies, pharmacotherapies, and other biological treatments can literally give life back to our patients. Since a major part of our focus is on inner, subjective experiences – thoughts, emotions, hopes, memories, and self-reflections – we are privileged to know our patients in ways that lead to a deep and fulfilling sense of connection. Our aim is to teach residents to arrive carefully at diagnoses by interviewing and understanding in ways that help patients reveal their painful inner lives. We want to prepare you to recognize and treat the many different conditions that are grouped as mental disorders and to learn how behavior and mental events are linked to that amazing organ – the brain. We have wonderful partners in the neurosciences that are now focused on studying the higher functions (e.g., memories, emotions, decision making) which are often dysregulated in our patients, allowing us to further elucidate theories of how vulnerabilities develop and how life events and treatments can interact in adverse as well as protective ways.

At Mount Sinai we want all residents to gain the knowledge base and clinical skills to practice clinical psychiatry, but we aim for more than that. The field of psychiatry continues to expand, and one’s ability to practice as a general psychiatrist is in some ways becoming outdated. Especially in an urban setting, a patient often seeks the expert for her/his condition. For a long time, psychiatrists have specialized according to population treated (e.g., geriatric, child) or method of treatment (psychotherapist, psychopharmacologist). However, we at Mount Sinai see psychiatry undergoing a new sort of differentiation – along the lines presaged by medicine and neurology – into subspecialties based on syndrome and/or disease processes (e.g., autism, bipolar disorders, anxiety disorders, attentional disorders, etc.). And, as some of the best treatments in psychiatry entail combining high-level psychopharmacology and illness-specific psychotherapy, we seek to train psychiatrists with clear areas of expertise in each. As in your undergraduate careers, we will encourage you to define a major or area of concentrated focus, and we aim for you to graduate with a valid sense of expertise that will merit you a position of distinction when you go on to further training, clinical practice, research, or teaching/administrative positions. Residents at Mount Sinai have an opportunity to develop individually-tailored programs in which they can focus their training in a defined clinical area of interest and develop into a specialist able to provide the most effective, evidence-based treatments for patients in that domain, both psychopharmacological and psychotherapeutic. These skills are honed through advanced training and mentorship and provide a basis for developing careers as not only expert clinicians, but also clinician-researchers, educators, administrators, advocate, theorists, and those who bring awareness of mental illness and potential treatments to the public.

In a similar way, we also prize our ability to train researchers who will lead and advance the field of psychiatry. The mentorship provided by world-renowned and highly productive leaders in the fields of neuroscience and psychiatry makes Mount Sinai’s dedicated Physician-Scientist Research Track, as well as our groundbreaking Residency + PhD Track, the ideal place to receive individualized advanced training in skills necessary to perform research to understand and treat psychiatric disorders.

In creating researchers and concentrated clinical experts, our approach allows for a high degree of flexibility, tailoring, and personalization as you determine your future as an effective contributor to the field of psychiatry and to the needs of psychiatric patients. We strive to provide an open, stimulating, and supportive environment for our residents. Residency education involves hard work, but there is joy and excitement in becoming a psychiatrist, and we intend for these years to be professionally productive and personally fulfilling. Again, welcome to Mount Sinai. We look forward to sharing with you our enthusiasm about the Mount Sinai Residency Program in Psychiatry.
Ronald O. Rieder, MD
Professor of Psychiatry & Vice Chair for Education
Director of Residency Program in Psychiatry
BA, Harvard University
MD, Harvard Medical School
Residency in Psychiatry, Albert Einstein College of Medicine

A career educator and mentor, Dr. Rieder is Vice Chair for Education and Director of Residency Education in Psychiatry at the Icahn School of Medicine at Mount Sinai. He joined the Mount Sinai faculty in 2007 after serving as Vice Chair and Director of Residency Education at Columbia University since 1979. He is the 2008 recipient of the American Psychiatric Association's highest award for education, the Vestermark Award, and he is a past President of the American Association of Directors of Psychiatric Residency Training. From 1970-1979, Dr. Rieder conducted research on schizophrenia at the National Institute of Mental Health, and he has continued to develop research training as well as clinical training for psychiatrists, nationally and at Mount Sinai. He has successfully created our department’s Physician-Scientist Research Track, and recently received an NIMH grant to fund a specialized Psychiatry residency + PhD Track.

Asher Simon, MD
Assistant Professor of Psychiatry
BA, Brown University
MD, Albert Einstein College of Medicine
Residency in Psychiatry, Mount Sinai School of Medicine
Fellowship, Mood & Anxiety Disorders, Mount Sinai School of Medicine
Candidate, Columbia University Center for Psychoanalytic Training & Research

Dr. Simon is the Associate Director for Residency Education in Psychiatry. He previously served as the Medical Director of the Continuing Day Treatment Program from 2005-2009, where he taught and supervised residents in the care of treatment-resistant patients using creative psychopharmacology and psychotherapy in an interdisciplinary systems-intensive focus. A dynamic and vibrant clinician educator since early in his residency, Dr. Simon has received multiple awards for his teaching from residents, medical students, and institutionwide, as well as recognition from national organizations including the American Psychiatric Association. Atop his attention to education, Dr. Simon has special interests in the phenomenology of psychosis, psychodynamic psychotherapy and psychiatric interviewing and formulation. He has authored articles on residency education in neuroscience and psychotherapy as well as the textbook, *Blueprints Clinical Cases in Psychiatry*. He is currently editing the psychiatry volume of the soon to be released *Mount Sinai Expert Guides* series.
HIGHLIGHTS OF OUR PROGRAM

DUAL APPROACH: RESEARCHERS AND CLINICAL EXPERTS

1. **Train psychiatrists with clear areas of expertise:**
   Residents have an opportunity to develop individually-tailored programs in which they can focus on **training in a defined clinical area of interest** and develop into a specialist able to provide the most effective treatments for patients in that domain, both psychopharmacological and psychotherapeutic. These skills are honed through **advanced training and mentorship** and provide a basis for developing careers as not only expert clinicians, but also clinician-researchers, educators, administrators, advocates, theorists, and those who bring awareness of mental illness and potential treatments to the public.

2. **Train researchers who will lead and advance the field of psychiatry:**
   The mentorship provided by world-renowned and highly productive leaders in the fields of neuroscience and psychiatry makes **Mount Sinai's two formal research tracks** the ideal place to receive individualized advanced training in clinical and research skills necessary to perform research to understand and treat psychiatric disorders.

   - We aim to attract and train **academically-minded residents** to become leading psychiatrist-neuroscience researchers and clinical leaders with defined areas of expertise.
   - We will inspire and assist trainees to **focus their educations on a defined, specialized area** of psychopathology or research (e.g., autism, schizophrenia, neuroimaging, genetics, etc.), in which they will receive advanced training and mentorship.
   - Some residents will be specifically trained to perform research in neuroscience and psychiatry and will be **provided with the time and resources** necessary for their success.
   - The education of psychiatric residents will focus on emerging knowledge regarding the pathogenesis of psychiatric disorders, so that they can employ such new models in treating the causative factors of psychiatric disorders.

INNOVATIVE, STATE-OF-THE-ART PSYCHIATRIC EDUCATION ACROSS ALL FOUR YEARS

- **Early breadth of exposure** via rotations on our general and specialized units leads to deepening experiences dictated by one’s own interests.
- **Exposure to an exceptionally diverse patient population** across ethnic, socioeconomic, gender, and, and diagnostic categories
- **Flexible scheduling** to tailor residents’ training experiences and facilitate subspecialization
- Opportunities for **longitudinal research with active mentorship** throughout training to allow for exploration and development of individual interests
- **Academic productivity expected of all residents**, culminating in a publication-worthy project
- Experience of training under **personable, accessible faculty** with national expertise in subspecialty areas of psychiatry
Leading experts at the Icahn School of Medicine at Mount Sinai—Drs. Charney, Buxbaum, Sklar, and Nestler—have released a new edition of the *Neurobiology of Mental Illness*. This cutting-edge textbook outlines the discoveries that have been made in the molecular and cellular basis of psychiatric disease over the past five years, in addition to explaining their clinical significance for diagnosing and treating patients.

Since it was first published in 1999, *Neurobiology of Mental Illness* has been the premier authority in the field for residents, researchers, and doctoral students. This reference book contains 32 new chapters with information spanning several levels of analysis, such as molecular biology and genetics, cellular physiology, neuroanatomy, neuropharmacology, epidemiology, and behavior. It also highlights timely topics in psychiatry such as the challenges of diagnosing mental disorders given the lack of scientific biomarkers, and how resources like the DSM-5 and the National Institute of Mental Health's Research Domain Criteria (RDoC) should be used.
HIGHLIGHTS OF OUR PROGRAM

PGY-1

Rotations on specialized psychiatric services:
- Inpatient Adult, Child/Adolescent, Geriatric, Substance, Forensics
- Psychiatric Emergency Service

- Didactics: Weekly curriculum on Interviewing, Diagnosis, Formulation, & Treatment
- Case conferences and clinical seminars
  - Weekly case conferences, focusing on psychiatric case formulation, symptom-specific interviewing, and patients’ subjective experiences, taught by Asher Simon, MD
  - Unit-specific case conferences led by senior faculty
  - Weekly seminar “Psychoanalytic Perspectives of Inpatient Psychiatry,” taught by the Medical Director of the New York Psychoanalytic Society & Institute
  - Twice weekly morning report with Ronald Rieder, MD, to discuss interesting cases and issues seen during short call and night float

- Internal Medicine Options: Choice of adult or pediatrics
  - 2 months adult or pediatric inpatient medicine
  - 1 month outpatient medicine
  - 1 month adult emergency medicine

- Neurology: 1 month inpatient neurology; 1 month neurology consult service
- On-Call: Short-Call and Night Float System, eliminating weekday overnight call

PGY-2

- Continue rotations on specialized inpatient and emergency psychiatric services
- Begin clinical work at the Bronx Veterans Affairs Medical Center
  - Outpatient substance abuse treatment, Outpatient evaluation clinic, Inpatient psychiatry, C/L
  - One of only 10 VA hospitals in the country designated by Congress as a Mental Illness Research, Education, & Clinical Center (MIRECC)
  - Opportunity to work in a nationally recognized center for PTSD treatment & research

- Weekly half-day of protected didactic/class time
  - Psychiatric Interviewing; Psychotherapy; Psychopharmacology; Neuroscience; Phenomenology; Social Psychiatry; Evidence Based Medicine; Research Design; Ethics; Specialized Topics
  - Weekly Process Group: A three-year group experience providing a forum to experience group dynamics and facilitate cohesion among classmates

- Elective time to explore and develop individualized clinical and research interests
- Initiation of outpatient psychotherapy experience under individualized supervision
- Training in Electroconvulsive Therapy (ECT)
- More intensive clinical teaching responsibilities:
  - Begin meeting with mentor/advisor to facilitate working on individual project, developing career trajectory, and navigating the national psychiatric landscape
  - On-Call at the Bronx VA, with attending back-up: night float system

“I was fortunate to spend a month of sub-internship at Mount Sinai prior to interviewing. During that time I experienced a working environment that fosters critical thinking, top patient care, and team camaraderie from the students, social workers, nurses, therapists, and doctors alike. That positive energy has persisted throughout my time as a resident, and I couldn’t be any happier with my choice of residency. As if that weren’t enough, you can’t beat New York City, and Mount Sinai’s psychiatry residency affords a work-life balance where you can really enjoy your time in this wonderful place.”

Jake Rosenberg, MD
PGY-2
HIGHLIGHTS OF OUR PROGRAM

PGY-3

- **Formal training and supervision** in the psychotherapies:
  - Long-Term and Brief Psychodynamic, Supportive, CBT, DBT, Interpersonal, Family/Couples, Group, Prolonged Exposure, Cognitive Processing, and others
  - Individualized supervision by senior psychotherapists, including psychoanalysts through Mount Sinai’s formalized affiliation with The New York Psychoanalytic Society & Institute
- **Longitudinal training** in the assessment and treatment of outpatients, including geriatric patients, children & adolescents, and the acutely and chronically ill
- **Longitudinal training** in the treatment of severely and persistently mentally ill patients in Mount Sinai’s Continuing Day Treatment Program
- **One half-day of elective time per week**, allowing residents to develop proficiency in specialized diagnostic and therapeutic modalities, or research
- **Didactics**: One day per week—protected time
  - Continuing longitudinal courses in Psychotherapy, Psychopharmacology, Neuroscience, Social & Community Psychiatry, and Continuous Case Conferences
- **On-Call**: Night Float System, in the dedicated Psychiatric Emergency Service, which is staffed by an Attending Psychiatrist 24/7 to maximize supervision of residents
- **Presentation of a clinical case for Grand Rounds**

PGY-4

- **8 months of elective time in specialized settings**, providing residents with mentorship and resources to develop clinical and/or research expertise
- **Continuation of long-term psychodynamic psychotherapy and supervision**
- **A more circumscribed longitudinal outpatient experience**, allowing residents to continue treating patients of their choosing and providing residents with more time for their own clinical and research interests
- **Didactics**: One day per week—protected time
  - Advanced courses in psychiatric interviewing, psychotherapy, psychopharmacology, careers in psychiatry, etc.
  - Continuation of Process Group
- **Training in Psychosomatic Medicine** (Consultation/Liaison Psychiatry) within one of the preeminent academic medical centers in the United States, with faculty who pursue various subspecialty work in transplant psychiatry, movement disorders, HIV psychiatry, and the psychiatric aspects of multiple sclerosis
- **No call duties**

“Coming from Texas, I was pleasantly surprised on my interview day by the warm and welcoming nature of Mount Sinai. I quickly found upon matriculation that this wasn’t just a song and dance put on for recruitment, but the true nature of the institution. At Mount Sinai, people are approachable and eager to collaborate. As a resident I feel well-supported in my clinical, educational, and even leisurely endeavors. I’ve appreciated Mount Sinai’s diversity of psychiatric experiences, and I’ve been able to explore the culture that NYC offers. I believe that having my experience at Mount Sinai allows me to be a better and happier psychiatrist.”

Brandon Johnson, MD
PGY-3
We have constructed our general residency program (NRMP: 1490400C0) to allow all residents the flexibility to use abundant elective time to explore specific aspects of psychiatry and develop special areas of expertise. In addition we have three formal tracks, two of which have separate NRMP numbers.

Of course, all applicants to the below tracks may also rank the categorical track.

- **Psychiatry Residency + PhD (PR+PhD) Track: 1490400C3**
  This first-of-its-kind program integrates PhD education with all elements of training in clinical psychiatry in 7 years. It is specifically designed for MD graduates who wish to obtain PhD-level research training and pursue an academic career in psychiatry.

- **Physician-Scientist Research Track: 1490400C2**
  Now in its sixth year, this specialty track offers maximal time for research over the 4 years of psychiatry residency and is designed for applicants who have previously completed PhDs or other substantial research training.

- **Global Mental Health Track (No separate NRMP match number)**
  Applications are made during the PGY-1 or PGY-2 years.

Applicants without a PhD but with substantial research experience are encouraged to apply for both of the research tracks and list both NRMP match numbers.

**Psychiatry Residency + PhD (PR+PhD) Track**

The Department of Psychiatry at Mount Sinai has been awarded NIMH support for this extraordinary program, which offers a second path to MD/PhD training. We plan to offer 2 places in this track each year. This opportunity is unique in the nation, and also offers the possibility of trainees receiving substantial financial advantages through the NIH’s Loan Repayment Program (up to $35,000/year for 4 years).

As the fields of neuroscience and genetics have advanced in knowledge base and research strategies and techniques, PhD-level training (or its equivalent) may be a necessity for both effective translational research and obtaining research funding. Unfortunately, the number of psychiatrist MD/PhD researchers is small. Additionally, while the NIH has long supported Medical Scientist Training Programs, the established method of combined MD/PhD training is inefficient, in that the period of intense research and PhD completion is followed by many years of clinical training; what follows is a long separation from research, leading to a decline in research skills, distance from the knowledge base and collaborators, and a need to retrain after residency. We have thus developed this innovative program as a new model of PhD training for psychiatrists wishing to conduct translational research.

Components of the PR+PhD program include

1. Completion of all experiences required by the American Board of Psychiatry and Neurology.
2. Completion of all requirements of the Icahn School of Medicine at Mount Sinai for the PhD degree in either Neuroscience or Biomedical Sciences (Genetics and Genomics).
3. Research done with close mentorship; training in writing research publications and grants; scientific career-building activities (presenting at meetings; joining neuroscientific professional organizations); and connecting with other scientists, including those in the residency’s Physician Scientist Track and other neuroscientists at Mount Sinai and beyond.

Clinical experiences are front-loaded but continue throughout the 7 years. The first year is a full intern year devoted to meeting residency requirements. For each of the following six years, 50% is “psychiatry residency (PR) time” and 50% is “NIMH-supported (PhD) time.” The 50% PR-time includes clinical training, core PR didactics, and research electives; the 50% PhD-
time is used for PhD didactics and research. For a breakdown of the Clinical, Research, and Didactic activities over the 7 years, please refer to the website and the table below.

<table>
<thead>
<tr>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
<th>Year 5</th>
<th>Year 6</th>
<th>Year 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuro</td>
<td>PhD Didactics</td>
<td>PhD Didactics</td>
<td>Research (PhD)</td>
<td>Research (PhD)</td>
<td>Research (PhD)</td>
<td>Research (PhD)</td>
</tr>
<tr>
<td>Medicine</td>
<td>Research (PhD)</td>
<td>Research (PhD)</td>
<td>Research (PhD)</td>
<td>Research (PhD)</td>
<td>Research (PhD)</td>
<td>Research (PhD)</td>
</tr>
<tr>
<td>Psych Inpatient</td>
<td>Psych Outpatient</td>
<td>Psych Outpatient</td>
<td>Research (PR)</td>
<td>Research (PR)</td>
<td>Research (PR)</td>
<td>Research (PR)</td>
</tr>
<tr>
<td>Clinical</td>
<td>Clinical</td>
<td>Clinical</td>
<td>Clinical</td>
<td>Clinical</td>
<td>Clinical</td>
<td>Clinical</td>
</tr>
</tbody>
</table>

All PR+PhD trainees are registered as psychiatry residents and paid in accordance with Mount Sinai Hospital House Staff salaries for each of their 7 years in the program. In years 4-7, when trainees are involved primarily in research, they may be eligible for NIH's Loan Repayment.

**Physician Scientist Track**

The Physician Scientist (Research) Track is designed for applicants who have previously demonstrated substantial experience in and aptitude for research.

Our Department of Psychiatry is consistently one of the top 15 psychiatric research departments in the United States as ranked by federal funding, and our Department of Neuroscience is #3, with two individual investigators listed among the top 10 funded PI's; information on federal grants can be viewed on our website. Also please see the Friedman Brain Institute’s “The Informant” for an overview of recent developments, including new recruits and grants. Additional information regarding foundation grants (e.g., Seaver Autism Center), is available upon request.

In addition to the clinical training provided by the psychiatry residency program, the PS Track offers
- Substantial protected time for research during each year of residency
- Additional protected time as-needed for conferences and presentation of work
- Extensive mentorship opportunities and career development
- The possibility of postgraduate residents joining their research teams and labs as fellows, allowing them supported time to further work toward career development awards.

**Time Allocated for Research in the PS Track**

PGY-1: 1-month block, for initial survey of research possibilities and meetings with potential mentors
PGY-2: 3-months full-time immersion with a lab or team, and 1-month rotating through various research centers to learn skills necessary for research evaluations
PGY-3: 30-50% time longitudinally throughout the year
PGY-4: 50-70% time for 10 months of the year

Since beginning in 2008, the PS Track has produced a number of highly regarded psychiatrist-scientists who have published in leading journals and obtained grant support. Descriptions of their research experiences are available on our website, and you are welcome to contact each of them to learn more about them, their work, their awards and publications, or their residency experiences.
PGY-2, -3, and -4 residents have the opportunity to pursue advanced electives in Mount Sinai's areas of expertise, some of which include the following:

- **Child and Adolescent Psychiatry**
  - Seaver Autism Center; Pediatric Mood and Anxiety Disorders Program; Center of Excellence for ADHD and Related Disorders (including adult ADHD); Learning and Development Center; Inpatient; Outpatient
- **Community and Public Psychiatry**
  - Administration; Assertive Community Treatment (ACT); Day Treatment
- **Consultation-Liaison Psychiatry**
  - Including programs in Multiple Sclerosis, HIV, Transplant, Movement Disorders
- **Division of Tic, OCD, and Related Disorders (DTOR)**
  - Clinical and Research; Child, Adolescent, and Adult.
- **Eating and Weight Disorders Research Program**
  - Including BDD and Appearance and Performance Enhancing Drug Use
- **Emergency Psychiatry**
- **Friedman Brain Institute, comprised of these Centers of Excellence:**
  - Brain Aging; Brain Imaging Core; Cognition & Neural Plasticity; Computational & Systems Neuroscience; Mood, Motivation & Addiction; Myelin Disorders: Mechanisms & Repair; Neural Injury & Repair; Neurodegeneration; Neurodevelopmental Disorders; Novel Approaches to Neurodiagnostics & Neurotherapeutics
- **Geriatric Psychiatry: Alzheimer's Disease Research Center; Inpatient; Outpatient**
- **Disaster & Global Mental Health: Belize, Liberia, India, Liberia, Japan, etc.**
- **Hospitalist and Administrative Psychiatry**
- **Mood & Anxiety Disorders Program**
- **Mood & Personality Disorders Program**
- **Neuroimaging**
- **Neuropsychiatry**
- **Neurostimulation:** ECT; TMS; DBS
- **Psychiatric Genomics, Genetics, and Epigenetics**
- **Psychotherapy Research and Clinical Program**
- **Psychotherapy**
  - DBT; Psychodynamic Psychotherapy; CBT; Schema Therapy; IPT; can begin psychoanalytic training during residency; Family/couples; Group; Exposure; etc.
- **Substance Use Disorders**
- **Suicide and Harm Reduction**
- **Traumatic Stress Studies Division**
  - PTSD; Holocaust survivors; Veterans; Innovative psychotherapies
- **Visiting Doctors Program**
- **World Trade Center Worker and Volunteer Program**

With the exciting new formation of the Mount Sinai Health System, we are now able to offer additional elective opportunities utilizing the other clinical sites (e.g., Center for Intensive Treatment of Personality Disorders (CITPD) at St. Luke’s at Mount Sinai).
**SOCIALIZING, RECREATION & ENRICHMENT**

- **Subsidized housing** available to all incoming residents, many within walking distance of the Medical Center.

- **Cosmopolitan location** on Museum Mile along the East Side of Manhattan adjacent to Central Park, within walking distance of the Metropolitan Museum of Art and the Guggenheim. Residents at Mount Sinai benefit from the abounding opportunities within the diverse cultural, educational, historic and gastronomic center of New York City.

- **The Mount Sinai Recreation Office** offers a wide range of discounts to help residents enjoy many of New York City’s cultural events, such as Broadway and Off-Broadway shows, movies, sporting events, amusement parks, restaurants, health clubs and spas, hotels, cell phone service, car rentals, and much more. Please see http://fusion.mssm.edu/recreation/index.cfm for more information.

- **Public transportation** is easily accessible and, within minutes, one can be at the United Nations, Rockefeller Center, Greenwich Village, Soho, Lincoln Center, Carnegie Hall, Times Square, Broadway Theatre District, South Street Seaport, Ellis Island, the Statue of Liberty, and the New York Public Library.

- Assisted referral to high quality, low cost personal psychotherapy (encouraged as part of the training experience) with scheduling flexibility to allow for convenient arrangements.

- **Residency-organized social activities**, including a book club, happy hours, a resident retreat, a thriving film club, and group outings.

*The Atrium, designed by I.M. Pei, on Mount Sinai’s main campus.*
Wayne Goodman, MD
Chair, Department of Psychiatry, Mount Sinai School of Medicine
Professor of Psychiatry and Neuroscience
BS, Columbia University
MD, Boston University
Residency in Psychiatry, Yale University School of Medicine

Prior to joining Mount Sinai in July 2009, Dr. Goodman was Director of the Division of Adult Translational Research and Treatment Development (DATR) at NIMH from 2007-2009, and before that, Chair of Psychiatry at the University of Florida. Dr. Goodman has conducted pioneering research in Obsessive Compulsive Disorder and is the principal developer of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the gold standard for assessing OCD. He is co-founder of the Obsessive Compulsive Foundation, the national patient advocacy organization. Dr. Goodman has published more than 200 scientific articles and has been principal investigator on NIMH-funded grants since 1992, and he previously served as Chair of the FDA's Psychopharmacologic Drug Advisory Committee. He participates in a monthly journal club for residents as well as being an advisor/mentor.

Dennis S. Charney, MD
Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai
President for Academic Affairs, Mount Sinai Health System
Professor of Psychiatry, Pharmacology and Systems Therapeutics, and Neuroscience
BA, Rutgers College
MD, Pennsylvania State College of Medicine
Residency in Psychiatry, Yale University School of Medicine

Dr. Charney is a world expert in the neurobiology and treatment of mood and anxiety disorders and the study of human resilience. He was recruited to Mount Sinai in 2004 as Dean of Research, becoming Dean of the School of Medicine in 2007 and unveiling a strategic plan that laid the foundation for 14 robust Research Institutes. Under his leadership Mount Sinai is in the top 20 in NIH funding, currently 5th in funding per faculty member. In 2013, he was named President for Academic Affairs for the newly-formed Health System and will oversee the Icahn School of Medicine's role as one of the most expansive training and research footprints in the nation. Initially at Yale, Dr. Charney later directed the NIMH's Mood and Anxiety Disorder Research Program. His work has led to new findings regarding the mechanisms of antidepressant drugs, the discovery of novel therapies for treatment resistant depression, and the psychobiological mechanisms of human resilience to stress. Dr. Charney has written more than 700 publications and many books. In 2000, he was elected to the Institute of Medicine.

Kenneth L. Davis, MD
President and CEO, Mount Sinai Health System
Professor of Psychiatry, and Pharmacology and Systems Therapeutics
BA, Yale University
MD, Mount Sinai School of Medicine
Residency in Psychiatry and Fellowship, Stanford University Medical Center

Dr. Davis was appointed CEO of The Mount Sinai Medical Center and Dean of the School of Medicine in 2003 and is now overseeing the creation of the Mount Sinai Health System. Widely recognized as a visionary leader who has placed Mount Sinai on a strong and dramatic growth trajectory, he began first as Chief of Psychiatry at the Bronx VA and then Chair of the Department of Psychiatry, where he launched Mount Sinai’s research program in the biology of schizophrenia and Alzheimer's disease. During these initial 15 years in psychiatry, his groundbreaking work opened new avenues for treatment and clinical trial design and led to the FDA’s approval of three of the first four drugs approved for Alzheimer's Disease. His work in schizophrenia has led to a new understanding of the role of myelination and oligodendrocytes in its pathophysiology, opening up an entirely new way of viewing and studying this disease. Dr. Davis has authored more than 550 articles and has been recognized as one of the most highly cited researchers in the field of brain diseases. In 2001 he was elected to the Institute of Medicine.
Charles H. Kellner, MD
Chief of the Division of Geriatric Psychiatry
and Director of the ECT Clinical Service
Professor of Psychiatry
BA, Cornell University
MD, Cornell University Medical College
Residency in Psychiatry, Cedars-Sinai Medical Center
Fellowship in Biological Psychiatry, National Institute of Mental Health

A national leader in ECT research, Dr. Kellner is the co-PI of a multi-site NIMH-funded study of maintenance ECT for geriatric depression, with Mount Sinai being one of two overall coordinating sites. For the past decade, he led the Consortium for Research in ECT (CORE) in the performance of NIMH-sponsored multi-site research protocols. From 1994 to 2004, he was the Editor-in-Chief of the *Journal of ECT*, and he is a member of the APA Task Force on ECT. Before coming to Mount Sinai in 2009, Dr. Kellner served as Chair of Psychiatry at the Rutgers–New Jersey Medical School, and from 1984-2002, he directed the ECT service at the Medical University of South Carolina. Credited with more than 250 publications, Dr. Kellner has also recently authored the text *Brain Stimulation in Psychiatry*.

Mary Sano, PhD
Professor of Psychiatry
Associate Dean for Clinical Research, Mount Sinai
Director, Alzheimer’s Disease Research Center (ADRC)
Director of Research and Development, JJP Bronx VAMC
BS, University of Massachusetts
PhD, City University of New York
Fellowship, Columbia University, College of Physicians and Surgeons

A neuropsychologist by training, Dr. Sano came to Mount Sinai from Columbia University/NYSPI to direct the Mount Sinai ADRC and is involved in designing and conducting clinical trials for Alzheimer’s disease, Parkinson’s disease, and mild cognitive impairment of aging. She directed the first multi-center trial of vitamin E and Selegline treatments to delay the clinical progression of Alzheimer’s disease, and has directed and published studies using a wide range of agents for the treatment and prevention of cognitive loss and dementia. She has also conducted funded research and published in the cognitive consequences of medical disease, including in renal and pulmonary conditions and in environmental exposures including anesthesia and second hand smoke. Her other areas of expertise include research in the development and evaluation of computerized and home-based cognitive and functional assessments, methods development for economic and quality of life outcomes, and the engagement of culturally and ethnically diverse populations in research efforts.

Hillel Grossman, MD
Associate Professor of Psychiatry
Director, Clinical Research Core of the ADRC
Medical Director, Mount Sinai Memory and Aging Center
BA, Yeshiva University
MD, University of Tennessee
Residency in Psychiatry, Johns Hopkins School of Medicine
Fellowship in Geriatric Neuropsychiatry, University of Rochester

Dr. Grossman is Team Leader of Geriatric Psychiatry at the Bronx VA, where he supervises residents and fellows. He co-directs the year-long PGY-2 didactic series on Method and Methodology in Descriptive Psychiatry (the “Phenomenology course”) with the aims of residents deepening their observational acumen in their second year and developing philosophical perspectives for their clinical work. Dr. Grossman's research is conducted through the ADRC, with support from the NIH institutes, National Institute of Aging, National Center for Complementary and Alternative medicine, and the VA. His research focuses on developing techniques for the early detection of Alzheimer’s dementia and novel treatments for cognitive and behavioral symptoms of dementia and aging. Dr. Grossman’s chief clinical interest and goal is the preservation of self-hood in dementia and aging.
Dan Iosifescu, MD  
Associate Professor of Psychiatry and Neuroscience  
Director of the Mood and Anxiety Disorders Program  
MD, Carol Davila University of Medicine and Pharmacy  
Residency in Psychiatry, Massachusetts General Hospital  
Fellowships in Research, Neuroimaging, and Psychopharmacology, Harvard Medical School  

Dr. Iosifescu is a psychopharmacologist who directs the Mood and Anxiety Disorders Program, focusing on expert clinical treatment and pursuing clinical studies of novel pharmacotherapies and device-based treatments. He also investigates treatments for cognitive deficits in mood disorders and biological markers of treatment outcomes, using neuroimaging and neurophysiology techniques. For the past few years, he has directed the residents’ PGY-2 and PGY-3 psychopharmacology courses. Before joining Mount Sinai in 2010, Dr. Iosifescu was at Massachusetts General Hospital as Director of Translational Neuroscience in the Depression Clinical and Research Program and Site Director of the NIMH Bipolar Trials Network.

Sophia Frangou, MD, PhD  
Professor of Psychiatry  
Chief, Psychosis Research Program  
BA/MD, University of Athens  
PhD, University of London  

A leading expert in schizophrenia and bipolar disorders, Dr. Frangou was recruited to Mount Sinai in 2013 to establish a clinical and translational psychosis program to rapidly transfer research in genetics, neuroimaging, and neurobiology into clinical trials and clinical care. Her research of the neural pathways of disease expression, vulnerability, and resilience, along with associated genetic risk factors has represented a paradigm shift in refining conceptual models for psychosis. Dr. Frangou previously worked as Head of the Section of Neurobiology of Psychosis at the Institute of Psychiatry in London and as a psychiatrist at the Maudsley Hospital. She was also Training Program Director of a dual doctorate and clinical certification track, which helped establish the national and international reputation of the Institute of Psychiatry in training. In her new position at Mount Sinai, Dr. Frangou will help train the next generation of translational neuroscientists and clinicians in psychosis.

Larry J. Siever, MD  
Professor of Psychiatry and Vice-Chair for VA Affairs  
Chief of Psychiatry, James J. Peters VA Medical Center  
BA, Harvard University  
MD, Stanford University School of Medicine  
Residency in Psychiatry, Harvard Medical School, Mclean Hospital  

Dr. Siever is Director of the VA's Mental Illness Research Education and Clinical Center. An internationally recognized leader in personality disorder research, he directs the federally funded Mood and Personality Disorders program at Mount Sinai with a focus on the neurobiological substrates that underlie borderline and schizotypal personality disorders. His present research on schizotypal PD employs neuroimaging and cognitive enhancement to explore dopaminergic abnormalities as part of the schizophrenia spectrum, and his work on BPD currently employs PET to identify receptor distributions. Dr. Siever has published over 360 peer-reviewed articles and is past president of the Society of Biologic Psychiatry. He is also a well-recognized teacher and clinician in the field of personality, as well as schizophrenia, affective, and impulse spectrum disorders. Dr. Siever teaches in the didactic curriculum, lecturing in the psychopharmacology and phenomenology courses.
Antonia New, MD
Director of Medical Student Education
Professor of Psychiatry
BA, Swarthmore College
MD, Cornell University Medical College
Residency in Psychiatry, NY Hospital – Cornell Medical Center

A mentor for medical students, residents, and fellows, Dr. New is involved in research, clinical work, and teaching at Mount Sinai. Her NIH and VA-funded research focuses on the neurobiology of borderline personality disorder, investigating the regulation of emotion using techniques such as functional and structural brain imaging, psychophysiology, neurocognitive tasks, and techniques in social neuroscience. Her work has examined the neural circuitry underlying the control of aggression, and more recently has employed theoretical frameworks from the philosophy of mind to understand the experiences of emotion in BPD. She also explores the effect of trauma in women with a particular focus on factors that create vulnerability and resilience to adverse consequences of traumatic experiences, also employing functional brain imaging and neurocognitive tasks. Most recently, she has begun to employ novel pharmacotherapies for personality disorders.

James Murrough, MD
Assistant Professor of Psychiatry and Neuroscience
BA, Emory University
MD, Tufts University School of Medicine
Residency in Psychiatry, Mount Sinai School of Medicine
Fellowship in Mood and Anxiety Disorders Research, Mount Sinai

Beginning early in residency at Mount Sinai, Dr. Murrough was involved in research in the Mood and Anxiety Disorders Program. Under the leadership of Dennis Charney, he began studying experimental therapeutics for treatment resistant conditions as well as developing research into the clinical neuroscience of major depression and other disorders. In addition to investigating brain mechanisms of antidepressant response using functional neuroimaging, a principle focus of his current research is the study of ketamine in treatment-resistant depression as well as rapid treatment of both chronic and acute suicidal ideation. Multiple residents, both on the research track as well as general adult psychiatry residents, have worked with him on his studies and look to him as a mentor. He co-directs a clinical seminar for neuroscience doctoral students and is also a significant presence in the residents' PGY-2 and PGY-3 psychopharmacology didactic series.

Rachel Yehuda, PhD
Professor of Psychiatry and Neuroscience
BA, Touro College
PhD, University of Massachusetts, Amherst
Postdoctoral Research Fellowship in Biological Psychiatry, Yale University School of Medicine

An internationally-recognized leader in the field of traumatic stress studies, Dr. Yehuda is the Director of the Traumatic Stress Studies Division at Mount Sinai, which includes the PTSD clinical research program and the Neurochemistry and Neuroendocrinology Laboratory at the Bronx VA. She has published more than 250 papers, chapters, and books in the fields of traumatic stress and the neurobiology of PTSD. Her current interests include the study of risk and resilience factors, psychological and biological predictors of treatment response in PTSD, genetic and epigenetic studies of PTSD, and the intergenerational transmission of trauma and PTSD. Dr. Yehuda’s research on cortisol has revolutionized the understanding and treatment of PTSD worldwide, and she has been awarded the renowned Max Planck Institute for Psychiatry 2004 Guest Professorship.
Andrew C. Aronson, MD
Associate Professor of Psychiatry
BA, University of Maryland
MD, Tufts University School of Medicine
Residency in Psychiatry, Mount Sinai School of Medicine
Graduate, New York Psychoanalytic Society and Institute

Dr. Aronson directs Ambulatory Psychiatry Services at Mount Sinai, where patients are seen in over 50,000 encounters annually. He is a member of the New York Psychoanalytic Society and Institute, to which he is a senior liaison within the Mount Sinai Department of Psychiatry. He has served as curriculum and clinical director for psychodynamic psychotherapy training in the Mount Sinai Department of Psychiatry for over 10 years and as Director of Medical Student Mental Health for the Icahn School of Medicine at Mount Sinai for over 20 years. He has been a recipient of Teacher of the Residency and Educator of the Residency awards in psychiatry at Mount Sinai, and the Excellence in Teaching award from the Institute of Medical Education. He is co-author of journal articles and publications concerning mood, psychosis, and anxiety related disorders, including a manual for the time-limited psychotherapeutic treatment of panic disorder.

Peter B. Dunn, MD
Director for Clinical Services, New York Psychoanalytic Society and Institute
Assistant Professor of Psychiatry
BS, City College of New York
MD, Albert Einstein College of Medicine
Residency in Psychiatry, Albert Einstein/Bronx State Hospital

At Mount Sinai for the past 10 years, Dr. Dunn teaches psychodynamics and personality disorders. Earlier in his career, he was the Associate Director of Residency Training at Albert Einstein, Director of Family Therapy at Downstate Medical Center, and lecturer in the School of Social Work at NYU. He currently teaches a highly regarded weekly case conference for the inpatient residents, in which he makes even the most complex topics clear and digestible. He has won multiple teaching awards at Mount Sinai, where he embodies the dictum that a teacher is what you are, not what you teach. A further effect of his teaching has been that each year, several enthusiastic residents have entered psychoanalytic training, at the NY Psychoanalytic and elsewhere. He has also been nationally honored as an educator by winning a coveted Career Teacher Award from the NIMH as well as the Edith Sabshin Teaching Award from the American Psychoanalytic Association.

Alicia Hirsch, PsyD
Clinical Director, Mount Sinai Center of Excellence for OCD and Related Disorders
Assistant Professor of Psychiatry
BA, University of Southern California
PsyD, California School of Professional Psychology

Dr. Hirsch joined the faculty at Mount Sinai in 2001, initially working as a psychologist and study therapist for the Traumatic Stress Studies Program under Dr. Rachel Yehuda. In 2005, she joined the Eating and Weight Disorders Program and was its Director of Clinical Services from 2006-2009. Currently Dr. Hirsch is the Clinical Director of the Mount Sinai Center of Excellence for OCD and Related Disorders. Dr. Hirsch co-directs (with Dr. Tom Hildebrandt) the residents’ Cognitive-Behavioral Therapy elective and didactics at Mount Sinai, where she is dedicated to teaching and supervising residents and psychology externs, with a focus on the importance of understanding and delivering evidence-based treatments for psychological disorders. She has extensive clinical experience and applies a range of techniques in the treatment of anxiety disorders, eating disorders, and relationship issues.
Bruce Levine, MD
Director of Education for VISN 3 MIRECC and Psychiatric at the James J. Peters VA Medical Center
Associate Clinical Professor of Psychiatry
BA, University of Rochester
MD, Albert Einstein College of Medicine
Residency in Psychiatry, Albert Einstein College of Medicine

Dr. Levine is currently the Director of Education for the MIRECC (Mental Illness, Research, Education, and Clinical Center), which was established by Congress with the goal of researching the causes and treatments of mental disorders and using education to put new knowledge into routine clinical practice. The Mount Sinai-affiliated VA is part of VISN 3 which is comprised of VA medical centers in NY and New Jersey and charged with focusing on serious mental illnesses. Prior to joining the MIRECC and Mount Sinai, Dr. Levine held positions of Associate Director of Residency Training in Psychiatry at the Albert Einstein College of Medicine and subsequently at New York University School of Medicine. He has also been the Clinical Director at Manhattan Psychiatric Center, and he is an examiner for the American Board of Psychiatry and Neurology. Dr. Levine has won numerous awards as an educator in his departments of psychiatry.

Marianne Goodman, MD
Clinical Professor of Psychiatry
Psychiatry Residency Site Director, James J. Peters VA Medical Center
BA, University of Pennsylvania
MD, University of California, San Francisco
Residency in Psychiatry, University of California, San Francisco

Dr. Goodman has been on the faculty of Mount Sinai and an attending at the James J. Peters VA Medical Center (JJPVAMC) for over 10 years. From 2001-2004, she ran the Mount Sinai Psychiatry Medical Student Program at JJPVAMC. A talented clinician and educator, she developed the Dialectical Behavioral Therapy (DBT) Program in 2002, and she continues to train residents and psychology interns in the technique. Beginning in residency and throughout her career, Dr. Goodman has received multiple awards for teaching. In addition to her interests in education and training, she is a funded investigator with grants in neuroimaging of DBT for borderline personality disorder and prevention of high-risk suicide. She has authored multiple articles on the neurobiology and psychotherapeutic treatment of borderline personality disorder.

Thomas Hildebrandt, PsyD
Assistant Professor of Psychiatry
Director, Eating and Weight Disorders Program
BS, Vanderbilt University
PsyD, Graduate School of Applied and Professional Psychology, Rutgers

Dr. Hildebrandt oversees both clinical care and research in the Eating and Weight Disorders Program. His clinical expertise includes men with eating disorders, CBT, Maudsley Family Therapy, behavioral weight-loss treatment, and treatment of body image disturbances, and he is one of the course directors for the residents’ 9-month CBT course. His research interests include developing and evaluating clinical interventions for eating and weight disorders (including Mirror Acceptance Treatment), the neuroendocrine contributions to eating and substance use disorders, the neural substrate of emotions in women with bulimia, and the consequences of appearance and performance enhancing drug (APED) use and anabolic androgenic steroid (AAS) use. His lab is currently conducting a novel longitudinal study to identify biomarkers of APED dependence and ultimately develop interventions and prevention programs for APED users.
Jeffrey H. Newcorn, MD
Director, Division of Child and Adolescent Psychiatry
Director, Center of Excellence for ADHD and Related Disorders
Associate Professor of Psychiatry and Pediatrics
BA, University of Rochester
MD, University of Rochester School of Medicine
Residency in Psychiatry, Tufts University
Fellowship in Child and Adolescent Psychiatry, Tufts – New England Medical Center

Dr. Newcorn is a nationally recognized researcher, educator, and mentor in the areas of ADHD, aggression, descriptive psychopathology of child and adolescent disorders, and child and adolescent psychopharmacology, with work spanning clinical and translational topics. He is a member of the steering committee of the NIMH-funded multicenter study “Multimodal Treatment of Children with ADHD (MTA),” the PI on an NIMH-funded ADHD Research Infrastructure Network, the PI or co-investigator on other NIMH-funded grants that examine the clinical, neurobiologic, genetic, neuroanatomic, and neurophysiologic basis of ADHD and its treatment, and the director of an active clinical trials program studying many of the newer medication treatments for ADHD. He has published over 150 peer-reviewed articles and book chapters and was a member of the DSM-IV advisory committees on child and adolescent disorders and disruptive behavior disorders.

John D. O’Brien, MD
Director of the Child and Adolescent Psychiatry & the Triple Board Residency Programs
Clinical Professor of Psychiatry
BS, St. Peter’s College
MD, Seton Hall College of Medicine and Dentistry
Residency in Psychiatry, St. Vincent’s Hospital & Medical Center of New York
Fellowship in Child and Adolescent Psychiatry, Columbia University
Graduate, William Alanson White Institute for Psychoanalysis

Dr. O’Brien teaches courses in the Child & Adolescent Psychiatry component of the adult psychiatry program and individually supervises adult psychiatry residents in the initial evaluation and ongoing treatment of children and adolescents in the outpatient clinic. A Life Fellow of the American Psychiatric Association, Dr. O’Brien is an esteemed and dedicated educator, having served as Program Director for three academic Child & Adolescent Psychiatry Residency programs in New York City and a member of the Steering Committee for certification in Child & Adolescent Psychiatry for the American Board of Psychiatry & Neurology.

Alexander Kolevzon, MD
Clinical Director, Seaver Autism Center for Research and Treatment
Associate Training Director, Child and Adolescent Psychiatry
Associate Professor of Psychiatry and Pediatrics
BA, University of Wisconsin, Madison
MD, Sackler School of Medicine at Tel Aviv University
Residency in Psychiatry, Mount Sinai School of Medicine
Fellowship in Child & Adolescent Psychiatry, Mount Sinai School of Medicine

A dedicated clinician, teacher, and researcher within the department, Dr. Kolevzon is involved in clinical and didactic education at many levels in the residency program. He serves as Clinical Director of the Seaver Autism Center for Research and Treatment, and supervises interested residents on many related research and clinical projects. He has clinical expertise in the psychopharmacology of autism and related conditions and his research is focused on developing new pharmacological treatments. He has written three books designed for medical student and resident education and a fourth textbook on Autism Spectrum Disorders published by the American Psychiatric Press. He is an active teacher, mentor, and clinical supervisor and has received many teaching awards as well as a grant to support innovative educational endeavors.
Barbara Coffey, MD, MS
Director, Tics and Tourette’s Clinical and Research Program
Professor of Psychiatry
Research Psychiatrist, Nathan S. Kline Institute of Psychiatric Research
BA, University of Rochester
MD, Tufts University School of Medicine
MS, Harvard School of Public Health
Residency in Psychiatry, Boston University School of Medicine
Fellowship in Child and Adolescent Psychiatry, Tufts University School of Medicine

Dr. Coffey is an internationally known specialist in tics and related problems who came to Mount Sinai from NYU in 2011. She was previously the Director of Pediatric Psychopharmacology at McLean Hospital and Director of the Tourette’s Clinics at McLean and Massachusetts General Hospitals between 1992 and 2001. Her research has focused on the clinical course, comorbidity, phenomenology, and treatment of Tourette’s Disorder and related problems, with a unique focus on comorbid anxiety and mood disorders. More recently, Dr. Coffey and her colleagues are investigating the neurobiology of TD with both genomics and neuroimaging. Dr. Coffey is an active clinical and research mentor for residents and has held leadership roles in AACAP and the World Psychiatric Association as well as Associate Editor of the Journal of Child and Adolescent Psychopharmacology.

Vilma Gabbay, MD, MS
Chief, Pediatric Mood and Anxiety Disorders Program
Associate Professor of Psychiatry and Neuroscience
BMedSc and MD, Tel Aviv University/Sackler School of Medicine
Residency in Psychiatry, Albert Einstein College of Medicine
Fellowship in Child and Adolescent Psychiatry, NYU School of Medicine
MS in Translational Medicine Research, NYU School of Medicine

One of the nation’s leading experts on pediatric mood disorders, Dr. Gabbay focuses on the neurological and immunological mechanisms that contribute to the development and maintenance of mood disorders in youth, with a special interest in depression. Recruited to Mount Sinai in 2012, she directs the Pediatric Mood and Anxiety Disorders Program where her research efforts involve using a comprehensive approach that combines in-depth clinical evaluations, novel therapies, cutting-edge neuroimaging techniques, and biological measures. She has adopted a dimensional investigative strategy that focuses on the relationship between anhedonia and the immune system. Her research has been funded by the NIH, NARSAD, the American Foundation for Suicide Prevention, and the Tourette Syndrome Association. Dr. Gabbay has received numerous awards and honors and has been published extensively in top-tier scientific journals.

Mary V. Solanto, PhD
Associate Professor of Psychiatry
Director, Adult ADHD Treatment Program
BA, Princeton University
PhD, State University of New York at Buffalo
NIMH Post-Doctoral Fellowship, Albert Einstein College of Medicine

As the clinical director of the Center of Excellence in ADHD and Related Disorders, Dr. Solanto teaches and supervises residents. Her research has focused on the cognitive and behavioral functioning of children with ADHD, the effects of psychostimulants, and the characteristics of the nosological subtypes of ADHD. She has been supported by grants from NIMH, NICHD, and NINDS. She has also explored neuropsychological functioning in adults with ADHD, after which she developed a novel CBT intervention—recently the focus of an NIMH-sponsored treatment-efficacy study—and is program director of the Mount Sinai Meta-Cognitive Therapy Program for Adults with ADHD. Among her numerous scholarly publications are her books, Stimulant Drugs and ADHD: Basic and Clinical Neuroscience (co-edited with Castellanos and Arnsten), and her manual for therapists (Cognitive-Behavioral Treatment of Adult ADHD: Targeting Executive Dysfunction).
Silvana Riggio, MD
Director of Consultation Liaison Service at James J. Peters VA
Professor of Psychiatry & Neurology
MD, University of Torino (Italy)
Residency in Neurology, Georgetown University School of Medicine
Residency in Psychiatry, New York Hospital – Cornell Medical Center
Post-Doctoral Fellowship in Neuropsychology, Johns Hopkins University School of Medicine

Dr. Riggio’s areas of expertise are Neuropsychiatry and Behavioral Management. She has an active presence at Mount Sinai and has won teaching awards from the Department of Psychiatry and from the Institute for Medical Education. She is trilingual in English, Italian, and French and maintains an internationally recognized clinical practice. She is the Director of the Consultation Liaison Service in the Department of Psychiatry at the James J. Peters VA, where she is responsible for teaching medical students, residents, and fellows. Over her career, she has been an investigator in multiple clinical trials on epilepsy and schizophrinia, and she is currently working with the CDC and the Department of Defense on issues related to the diagnosis and management of traumatic brain injury. She has published extensively in both the Psychiatric and Neurologic literature, and she has edited four books.

Kim Klipstein, MD
Director, Behavioral Medicine and Consultation Psychiatry
Associate Professor of Psychiatry
BA, Cornell University
MD, Cornell University Medical College
Residency in Psychiatry, NY Hospital – Cornell & University of California – San Francisco

Dr. Klipstein is the Director of Behavioral Medicine and Consultation Psychiatry at Mount Sinai and the Director of the Psychosomatic Medicine Fellowship. She provides direct supervision to residents rotating on the consultation–liaison service at the Mount Sinai Hospital, serves on the Education Committee of the psychiatry residency program, and teaches seminars on capacity assessment and other topics related to consultation–liaison psychiatry during the PGY-II year. Her professional interests include women’s mental health during pregnancy and the post-partum as well as psychiatric manifestations of liver disease and organ transplantation. She has recently been focused on further extending the scope of psychiatric consultant services within the hospital, in both inpatient and outpatient settings, developing new affiliations with oncology, cardiac transplant, and internal medicine associates, in addition to pre-existing collaborations with a multitude of other services.

James J. Strain, MD
Professor of Psychiatry
BS, University of Michigan
MD, Case Western Reserve University
Residency in Psychiatry and Research Fellowship, University Hospitals of Cleveland
Graduate, New York Psychoanalytic Institute

With a profession-long interest in the psychiatric care of the medically ill, Dr. Strain has directed C-L programs at Albert Einstein College of Medicine and at Mount Sinai and has trained more than 120 fellows in psychosomatic medicine. He has received multiple NIMH and teaching grants to pioneer research into the mental health training of non-psychiatric physicians, the compliance of physicians with research protocols, and the development of an electronic health record for psychiatric and medical comorbidity which has been employed internationally. He helped establish the Ethics in Medicine program at Mount Sinai and was the only psychiatrist on the Institute of Medicine (IOM) committee-developed Handbook for the Development of Guidelines for the Practice of Medicine. He has been active in the development of DSM-IV and DSM-5 adjustment and stress-related disorders. Dr. Strain has over 500 publications and has given more than 750 national and international lectures on the diagnosis and treatment of psychiatric and medical co-morbidity (visiting 210 countries). He has received the Hackett Award (the highest citation given for C-L Psychiatry) among others, as well as 15 endowed lectureships.
Sabina Lim, MD, MPH
Associate Professor of Psychiatry
Vice Chair for Clinical Affairs
BS, University of Michigan
MPH, Columbia University
MD, State University of New York at Buffalo School of Medicine
Residency in Psychiatry, Yale-New Haven Hospital

Before joining Mount Sinai in 2012, Dr. Lim was the Executive Director of the Yale-New Haven Psychiatric Hospital, having previously held various leadership roles in Yale’s Department of Psychiatry, including Associate Residency Program Director. At Mount Sinai, Dr. Lim oversees operations and strategic developments for all clinical activities related to mental health, including patient care, safety, and quality of care in inpatient, outpatient, transitional care, and outreach. She is active in developing mechanisms and metrics to assess outcomes and improve psychiatric services. During this time of rapid change in health care reform as well as in the new context of the Mount Sinai Health System, Dr. Lim is working to implement new ambulatory psychiatric programs at Mount Sinai, which involves developing innovative and cost-effective systems of care that span academic and community settings. She is also interested in collaborations with other departments and disciplines to coordinate behavioral health care across the health system.

Alejandra Durango, MD
Medical Director, Continuing Day Treatment Program
Assistant Professor of Psychiatry
BA, Johns Hopkins University
MD, University of Pennsylvania School of Medicine
Residency in Psychiatry, Mount Sinai
Fellowship in Public Psychiatry, Columbia University/NYSPI

As Medical Director of Mount Sinai’s Continuing Day Treatment Program, Dr. Durango directly supervises residents as they provide care for individuals with serious mental illness (SMI) in the intensive outpatient setting. She is involved in resident didactics as a co-director of the Psychiatry in the World course, focusing on the Community Psychiatry module in the PGY-3 year. Recovery, service delivery, and the treatment of persons with SMI, particularly schizophrenia spectrum disorders, are among her professional interests.

Craig Katz, MD
Associate Clinical Professor of Psychiatry and Medical Education
Director, Mount Fellowship in Global Mental Health
BA, Harvard University
MD, Columbia University College of Physicians and Surgeons
Residency in Psychiatry, NY Presbyterian Hospital – Columbia University/NYSPI
Fellowship in Forensic Psychiatry, New York University School of Medicine

Dr. Katz has served in numerous clinical and administrative roles since joining Mount Sinai in 2000, including being Director of Psychiatry Emergency Services and Director of Acute Care Psychiatry Services. He co-founded and directed the World Trade Center Worker/Volunteer Mental Health Monitoring and Treatment Program. Dr. Katz also co-founded Disaster Psychiatry Outreach in 1998 as a charitable organization to provide voluntary psychiatric care to people affected by disasters. He has been principal author of a training program in disaster mental health for the Medical Society of the State of New York, and a member of the advisory panel of the Aircraft Casualty and Emotional Support Services, and his work has extended as far as El Salvador, Sri Lanka, and Japan. He has received multiple teaching awards and was nominated as a faculty member to the Mount Sinai chapter of AOA. Dr. Katz joined Mount Sinai’s Office of Academic and Student Affairs in 2009, where he now holds the position of Director of Professional Development.
Eric J. Nestler, MD, PhD
Director, Friedman Brain Institute
Nash Family Professor and Chair, Department of Neuroscience
Professor of Psychiatry, Pharmacology and Systems Therapeutics
BA, Yale University
MD & PhD, Yale University School of Medicine
Residency in Psychiatry and Fellowship in Pharmacology, Yale University School of Medicine

Dr. Nestler came to Mount Sinai in 2008, after spending eight years as the Lou and Ellen McGinley Distinguished Professor and Chair of the Department of Psychiatry at The University of Texas Southwestern Medical Center. Prior to that, from 1987-2000, he served on the Yale faculty, eventually as the Elizabeth Mears and House Jameson Professor of Psychiatry and Neurobiology and Director of the Division of Molecular Psychiatry. Dr. Nestler is a member of the Institute of Medicine (1998) and a Fellow of the American Academy of Arts and Sciences. The goal of his research is to understand the molecular mechanisms of addiction and depression, based on animal models, and to use this information to develop improved treatments.

Schahram Akbarian, MD, PhD
Chief, Division of Psychiatric Epigenetics
Professor of Psychiatry and Neuroscience
MD & PhD, Freie Universitaet Berlin, Germany
Residency in Psychiatry, Massachusetts General Hospital
Fellowships, Whitehead Institute for Biomedical Research in Cambridge and UC Irvine

A neuroscientist and psychiatrist who studies epigenetic determinants of human brain development, Dr. Akbarian joined Mount Sinai in 2012 from the University of Massachusetts, where he served as the Director of the Brudnick Neuropsychiatric Research Institute. Dr. Akbarian studies the molecular bridge between genes and the environment and has recently developed methods to 1) chart epigenetic markings in brain cells; 2) present an epigenetic risk architecture for nerve cells from subjects with autism and schizophrenia; 3) study mutant mouse models with altered brain histone methylation for novel means to treat depression and psychosis; 4) explore epigenetic signatures unique to the human brain; and 5) push the frontiers in human brain research, including identifying the spatial arrangement of the “genome in 3D.” Dr. Akbarian sits on the Scientific Advisory Board of the Brain & Behavior Research Foundation (formerly NARSAD) and serves on editorial boards of Biological Psychiatry, Neuropsychopharmacology, Schizophrenia Bulletin, and European Neuropsychopharmacology.

Pamela Sklar, MD, PhD
Chief, Division of Psychiatric Genomics
Professor of Psychiatry, Neuroscience, and Genetic and Genomic Sciences
BA, St. John’s College
MD & PhD (Neuroscience), Johns Hopkins School of Medicine
Residency in Psychiatry, Columbia Presbyterian Medical Center/NYSDPI

Dr. Sklar is a neuroscientist, human geneticist, and psychiatrist who is founding director of the newly-established Division of Psychiatric Genomics. She has developed world-renowned programs for the genetic study of bipolar disorder and schizophrenia through her leadership positions in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) genetics program, the International Schizophrenia Consortium, the International Cohort Collection for Bipolar Disorder, and the Psychiatric Genome-wide Association Disorder Consortium. Prior to joining Mount Sinai in 2011, Dr. Sklar was a founding member of and served as Director of Genetics for the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. She was also Associate Director of the Psychiatric and Neurodevelopmental Genetics Unit in the Center for Human Genetics Research at MGH. She received much of her research training in the laboratories of Solomon Snyder at Johns Hopkins and Nobel Laureate Richard Axel at Columbia.
Joseph D. Buxbaum, PhD
Professor, Departments of Psychiatry, Neuroscience, and Genetics and Genomic Sciences
G. Harold and Leila Y. Mathers Professor of Geriatrics and Adult Development
Vice Chair for Research, Department of Psychiatry
Director, Seaver Autism Center
BSc, Touro College
MSc & PhD, Weizmann Institute of Science
Postdoctoral Fellowship, Rockefeller University

Dr. Buxbaum joined Mount Sinai in 1997 as Head of the Laboratory of Molecular Neuropsychiatry, a position he still holds. He became Director of the Seaver Autism Center in 2008, and in 2010 became the Vice Chair for Research in the Department of Psychiatry. Dr. Buxbaum’s research focuses on identifying and characterizing genes that contribute to autism susceptibility. His laboratory has identified common and rare genetic variants that underlie autism spectrum disorders and has developed model systems in which novel therapeutics can be tested. In addition, Dr. Buxbaum has taken a lead in several international consortia, most recently the Autism Sequencing Consortium aimed at sequencing 20,000 exomes. He is the co-editor-in-chief of the journal *Molecular Autism* and co-editor of the *Neuroscience of Autism Spectrum Disorders* with Mount Sinai’s Patrick R. Hof.

Yasmin Hurd, PhD
Director, Center of Excellence in Mood, Motivation, and Addiction, Friedman Brain Institute
Director, Mount Sinai MD/PhD Program
Chair, Minority Health Research Committee (MHRC)
Professor of Psychiatry, Neuroscience, & Pharmacology and Systems Therapeutics
BA, State University of New York, at Binghamton
PhD, Karolinska Institute, Stockholm, Sweden
Post-doctoral Fellowship in Functional Neuroanatomy and Neuroendocrinology, NIMH

Dr. Hurd studies the neurobiology underlying substance abuse and related disorders. Her multidisciplinary research employs a translational approach in examining molecular and neurochemical events in the human brain and comparable animal models in order to ascertain neurobiological correlates of behavior. A major focus of her research—based on the interrelationships of genetic vulnerability, epigenetic mechanisms, neuropsychopharmacology, and prenatal neurodevelopment—is directed to risk factors of addiction disorders, including the effects of developmental exposure to drugs of abuse. She is also attempting to identify genes in the mesocorticolimbic system, which regulates emotional function.

Rita Z. Goldstein, PhD
Professor of Psychiatry and Neuroscience
Director, Brain Imaging Core, Friedman Brain Institute
Chief, Neuropsychimaging of Addiction and Related Conditions (NARC)
BA, Tel Aviv University
PhD, University of Miami
Post-Doctoral Fellowship, NIMH and Brookhaven National Laboratory

Recruited to Mount Sinai in 2013 from Brookhaven National Laboratory, Dr. Goldstein explores impaired cognitive and emotional functioning in drug addiction and other disorders of self-control. To explore underlying neurobiology, she has formulated a model—Impaired Response Inhibition and Salience Attribution— which uses multiple modalities, including MRI, EEG/ERP, PET and neuropsychological testing. Her additional interests include pharmacological fMRI, neurofeedback with Brain Computer Interface, and TMS. She has also been scrutinizing the contribution of individual differences, including polymorphisms in monoaminergic genes, to addiction and aggression, with a focus on neural mechanisms underlying reinforcement learning and extinction, choice and decision-making, and self-awareness and insight into severity of illness.